Specialty Vision is an online directory, not a healthcare provider. Listed practices are not owned or operated by us.

Specialty Vision is an online directory and does not provide healthcare services. Listed practices and doctors are not owned, operated, or employed by Specialty Vision.

Light Therapy for Dry AMD: Is It Right for You If You Already Have Geographic Atrophy?

Light Therapy for Dry AMD at a Glance

Light Therapy for Dry AMD at a Glance

Do you already have geographic atrophy from dry AMD? Then this light therapy is likely not the right fit. Valeda light therapy was authorized for people with early and intermediate dry AMD who have not reached late-stage geographic atrophy1. Geographic atrophy is the late stage of dry AMD. In it, small patches of the retina have already died. Light cannot bring those cells back. You still have good choices. They are just different ones, and this page walks you through them.

Photobiomodulation is a treatment that shines specific colors of low-level light into the eye to try to support struggling retinal cells. The Valeda system delivers yellow (590 nm), red (660 nm), and near-infrared (850 nm) light in a series of nine short sessions over three to five weeks, repeated every four months2. It is not a laser that burns tissue and not an injection. The idea is gentle stimulation, not surgery.

The single most useful step is to confirm exactly what stage of dry AMD you have, because the answer to 'am I a candidate' turns entirely on that. A retina specialist can stage AMD using optical coherence tomography (OCT), a quick scan that shows whether you have drusen, intermediate changes, or established geographic atrophy. Bring that information to any conversation about light therapy so the decision is based on your retina, not a general brochure.

How Valeda Light Therapy Works and What a Course Involves

The working theory is about energy inside the cell. In photobiomodulation, light energy absorbed by parts of the cell is thought to stimulate the mitochondria, the cell's tiny power plants, increasing energy (ATP) production and reducing inflammation and harmful oxidative stress2. In early and intermediate AMD, the goal is to keep aging retinal cells working a little longer. This is a mechanism supported by laboratory reasoning and trial results, not a cure, and it does not rebuild retina that has already been lost.

Light therapy is a schedule, not a one-time visit. In the main 24-month study, patients received nine sessions over three to five weeks, and that series was repeated six times, once every four months2. Each session is painless and takes only minutes per eye. Because the benefit seen in studies came from repeating the courses, committing to the full schedule matters, and so does asking a clinic what happens if you miss a series.

The pivotal trial studied a specific group. LIGHTSITE III enrolled 100 patients (148 eyes) with intermediate dry AMD, with drusen and/or geographic atrophy that did not involve the center of vision, and vision between 20/32 and 20/1003. After four treatment series, at month 13, treated eyes gained on average 5.4 letters on the eye chart versus 3.0 letters in the sham group, and fewer treated eyes developed new geographic atrophy3. Those are modest, real gains in the studied group, not a promise of restored sight.

Who Is a Good Candidate for Light Therapy

Candidacy is defined by your AMD stage and your vision. The therapy is intended for adults with early or intermediate dry AMD who have not yet progressed to late-stage geographic atrophy1. In the trial, the eyes that qualified had vision in the 20/32 to 20/100 range and had drusen or atrophy that spared the very center of the macula3. If that describes you, light therapy is a reasonable option to discuss.

Geographic atrophy means the retinal cells in those patches are already gone, and light cannot bring dead tissue back. Because the therapy was authorized specifically for patients who have not progressed to late-stage geographic atrophy, established central atrophy places you outside the group where benefit was shown1. That does not mean nothing helps; it means the goal shifts from the light-therapy question to slowing the atrophy you already have, which is covered below.

Staging is not a guess you can make at home. A retina specialist uses OCT imaging and a dilated exam to distinguish drusen and intermediate AMD from geographic atrophy, which decides which treatments even apply to you. Ask directly: 'Do I have geographic atrophy, and does it involve the center of my macula?' The answer sorts you into one path or the other.

Who Should Not Use Light Therapy, or Should Wait

Two groups fall outside the studied use. Light therapy was not intended for wet (neovascular) AMD or for eyes that have progressed to late-stage geographic atrophy1. Wet AMD, where abnormal blood vessels leak under the retina, needs its own treatment (usually injections that block a growth factor) and should be managed first. If you have advanced central atrophy, the studied benefit does not apply to you.

One trial finding deserves an honest mention. In LIGHTSITE III, slightly more treated eyes developed wet AMD than sham eyes, about 5 of every 100 treated eyes (5 of 91) compared with about 2 of every 100 sham eyes (1 of 54)3. The numbers are small and the finding needs longer study, but it is a reason to make this a shared decision with a retina specialist rather than a routine add-on, and a reason to keep monitoring your vision after starting.

Practical factors matter too. If you cannot commit to repeated session series, if an active eye problem such as a fresh infection or uncontrolled wet AMD needs attention first, or if your stage has not been confirmed on OCT, it is reasonable to wait. Because the benefit in studies came from completing repeated treatment courses over two years, an incomplete course is unlikely to deliver what the trial showed2. There is no harm in settling these questions before you begin.

What Can Help If You Already Have Geographic Atrophy

For established geographic atrophy, the treatments that target the atrophy itself are injectable drugs. Two complement-inhibitor drugs, pegcetacoplan and avacincaptad pegol, are authorized to slow the growth of geographic atrophy and are given as injections into the eye4. In trials, pegcetacoplan slowed atrophy growth by about 16 to 22 percent over two years, and avacincaptad pegol slowed it by about 14 percent over one year4. These slow the process; they are not a cure.

It is important to set expectations honestly. These drugs slow how fast the atrophy spreads, but in the trials they did not improve or restore vision that had already been lost4. They also carry their own risks. A small share of patients, roughly 5 to 7 of every 100, developed wet AMD, and rare but serious inflammation inside the eye has been reported4. Whether the trade-off is worth it is a personal decision to make with a retina specialist.

Whatever your stage, supportive steps help. Low-vision rehabilitation, good lighting and magnifiers, not smoking, and the AREDS2 nutritional formula for intermediate AMD all have a role. Because geographic atrophy changes central vision over time, home monitoring and regular retina follow-up let your team act early if wet AMD develops on top of it. Your options are not limited to a single device.

What to Discuss at Your Consultation

Go in with your stage confirmed and your priorities clear. The decision usually comes down to three things: what stage your AMD is, how much vision you currently have, and whether you can commit to the repeating schedule. Because the therapy was studied in intermediate dry AMD and not in advanced geographic atrophy, confirming your stage is the first thing to settle3. If you already have central atrophy, the conversation should turn to slowing it instead.

Your OCT scans, your list of medications, and a note of any prior injections or eye surgery all help your specialist give you a straight answer. Ask whether your other eye is at a different stage, since the two eyes can need different plans. A good consultation ends with you knowing which stage you are in and which treatments actually apply to that stage.

Light therapy is generally paid for out of pocket, and pricing varies by clinic, so ask for the current cost of a full two-year course, not just one session. Weigh that against the modest, stage-specific benefit shown in studies. If you have geographic atrophy, ask your clinic to explain why they are or are not recommending the atrophy-directed injections instead.

Risks, Limits, and a Realistic Outlook

Set expectations to match the evidence. In the trial, the average benefit was a few letters of vision in eyes with intermediate dry AMD, not a reversal of the disease3. No eye-care treatment can promise a personal result, and anyone guaranteeing that light therapy will restore your sight is going beyond what the data support. The honest framing is a modest slowing and small support in the right stage.

The therapy itself is low-level light and is generally well tolerated. The main safety signal to weigh is the slightly higher rate of conversion to wet AMD seen in treated eyes in LIGHTSITE III, which is why ongoing monitoring is part of any plan3. Report any sudden change in your vision promptly so wet AMD can be caught and treated early.

This is a young field. The main supporting evidence comes from a single pivotal trial in intermediate dry AMD, so the long-term durability of the benefit is still being studied3. That is not a reason to dismiss it for the right patient, but it is a reason to keep your expectations grounded and to revisit the plan as more data arrive.

When to Call Your Eye Doctor

Some changes should not wait for your next scheduled visit. Call your eye doctor the same day if you notice any of these:

  • A sudden drop in vision in one eye
  • New or worsening distortion, where straight lines look bent or wavy
  • A new dark or blank spot in your central vision
  • A curtain or shadow moving across your side vision, or a sudden shower of new floaters and flashes

These can be signs that dry AMD has converted to wet AMD or that another retinal problem has developed, both of which are treated far better when caught early. Same-day care protects vision; waiting can cost it.

Between visits, simple home monitoring helps. Use an Amsler grid as your doctor directs, checking one eye at a time, and note any new waviness or missing areas. Because AMD can change gradually, keeping your scheduled retina follow-up lets your team compare OCT scans over time and adjust the plan before vision is lost. Regular monitoring is the quiet part of AMD care that does the most good.

Dry AMD, and especially geographic atrophy and light therapy decisions, are managed by a retina specialist, not by a routine glasses check. If your optometrist finds AMD changes, ask for a referral so staging and treatment choices are made by someone who treats the retina every day. That is the person who can tell you honestly whether light therapy fits your eye.

Common Questions About Light Therapy for Dry AMD

No. Geographic atrophy means those retinal cells have already died, and light cannot regrow them. Valeda light therapy was authorized for early and intermediate dry AMD in eyes that have not progressed to late-stage geographic atrophy, so established atrophy is outside its studied use1. If you have geographic atrophy, the more relevant conversation is about the injectable drugs that slow atrophy growth, and about low-vision support to make the most of the sight you have.

No, they are different treatments for different stages. Light therapy shines low-level light into the eye and is studied for intermediate dry AMD. The injections, pegcetacoplan and avacincaptad pegol, are drugs placed into the eye that are authorized to slow the growth of established geographic atrophy4. One aims to support earlier-stage cells; the other aims to slow late-stage atrophy. Your stage decides which conversation applies to you.

Expect modest results, and only in the right stage. In the pivotal trial, treated eyes with intermediate dry AMD gained on average 5.4 letters versus 3.0 letters in the comparison group at 13 months3. That is a few letters on the chart, not a return to normal sight. No treatment can promise a personal outcome, so be cautious about any clinic that guarantees a specific result.

The light sessions themselves are painless and generally well tolerated. The main safety signal was a slightly higher rate of conversion to wet AMD in treated eyes, about 5 of every 100 treated eyes compared with about 2 of every 100 sham eyes in the trial3. The numbers are small and need longer study, but they are a reason to keep monitoring your vision and to treat this as a decision made with a retina specialist.

Light therapy is a repeating schedule. In the study, patients had nine sessions over three to five weeks, and that series was repeated every four months over two years2. Each session takes only minutes, but the commitment adds up. Ask any clinic for the full two-year plan and cost up front, because the benefit in studies came from completing the repeated courses, not a single visit.

More Questions, and What to Ask Your Doctor

The two eyes can be on different paths, and that is common in AMD. Staging with OCT tells your specialist which eye, if any, still fits the intermediate stage where light therapy was studied, and which eye has progressed to atrophy needing a different approach. Each eye is assessed on its own, so you may hear one recommendation for one eye and a different one for the other.

No, and this is important to understand before starting them. In their trials, pegcetacoplan and avacincaptad pegol slowed how fast geographic atrophy grew but did not improve or restore vision that had already been lost4. They also carry risks, including a small chance of developing wet AMD. Whether slowing atrophy is worth repeated injections is a personal decision to weigh carefully with your retina specialist.

In most cases it is paid for out of pocket, and pricing varies by clinic, so ask for the full cost of a two-year course rather than a single session. Weigh that cost against the modest, stage-specific benefit shown in studies. If you have geographic atrophy, ask specifically why light therapy is or is not being recommended for your stage before you commit to paying.

Yes. Not smoking, eating a diet rich in leafy greens and fish, using the AREDS2 formula if your doctor advises it for intermediate AMD, and monitoring with an Amsler grid all help. Because AMD can quietly progress or convert to wet AMD, regular retina follow-up and prompt reporting of new distortion let problems be caught while they are still treatable. These steps support any treatment path you choose.

  • What stage is my dry AMD in each eye, and do I have geographic atrophy?
  • Does my atrophy involve the center of my macula?
  • Given my stage, is light therapy likely to help me, or is another treatment a better fit?
  • If I have geographic atrophy, are the atrophy-slowing injections right for me, and what are their risks?
  • What is the full cost and schedule of a complete course, and what monitoring will I need?

Specialty Vision
Privacy Overview